2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-11111217-B2
Application number	US-202017068985-A
Country	US
Kind code	B2
Filing date	Oct 13, 2020
Priority date	Aug 6, 2018
Publication date	Sep 7, 2021
Grant date	Sep 7, 2021

Abstract

The compound 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-5-ol:

and its use are disclosed. The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.

First claim

We claim:

1. A pharmaceutical composition comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier wherein the pharmaceutical composition is suitable for oral or parenteral administration.

2. The pharmaceutical composition of claim 1 , wherein the carrier is suitable for oral administration.

3. The pharmaceutical composition of claim 1 , wherein the carrier is suitable for parenteral administration.

Assignees

• Univ Leland Stanford Junior

Inventors

• Banister Samuel D
• Engleman Edgar
• Nguyen Khoa D
• Smith Mark

Classifications

• C07F9/65068

  condensed with carbocyclic rings or carbocyclic ring systems · CPC title

• C07D277/66

  with aromatic rings or ring systems directly attached in position 2 · CPC title

• C07D235/08 Primary

  Radicals containing only hydrogen and carbon atoms · CPC title

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title